ClinicalTrials.gg
TerminatedNCT05191472Updated Jan 15, 2025Results posted

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

A Phase 2 interventional study of Pembrolizumab in Multiple Myeloma, Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Alfred Chung, MD. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Alfred Chung, MD · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Why this study was terminated
Slow Accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing pembrolizumab in Multiple Myeloma — none open to participants now, none under way, none of them phase 3. pembrolizumab · Multiple Myeloma.

Enrollment
12th of 17
3 · median 13
Started
2022
with 2 others
Phase 2
10 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Alfred Chung, MD

Among the 17 studies testing pembrolizumab in Multiple Myeloma, this one is the 12th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 2, and was the 15th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 17 studies testing pembrolizumab in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pembrolizumab in Multiple Myeloma as a file.
02

Study summary

This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the overall response rate (ORR) of pembrolizumab in patients with relapsed or refractory multiple myeloma (MM) (RRMM) after anti-B-cell receptor maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapies.

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of pembrolizumab in participants who relapsed or were refractory to anti-BCMA CAR-T therapies.

II. To evaluate the depth of response for patients treated with pembrolizumab who had previously relapsed after or were refractory to anti-BCMA CAR-T therapies.

III. To evaluate time-to-event outcomes, including time-to-next treatment (TNT), progression-free survival (PFS), and overall survival (OS) after initiation of pembrolizumab therapy.

EXPLORATORY OBJECTIVE:

I. To explore the immune profile after pembrolizumab treatment, including changes in absolute lymphocyte count (ALC) and lymphocyte subsets by flow-cytometry.

OUTLINE:

Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Participants will be followed for at least 30 days after last treatment or removal from study, or until death. Participants who have completed 35 cycles of therapy or discontinued treatment for reasons other than disease progression will be followed for up to 1-year, until removal from study, start of new anti-cancer therapy, or death.

03

Conditions studied

  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma

Browse trials for

Keywords

  • CAR-T
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female participants who are 18 years of age or older on the day of signing with confirmed diagnosis of multiple myeloma will be enrolled in this study.
  2. Ability to understand a written informed consent document, and the willingness to sign it or a legally acceptable representative (if applicable).
  3. Have an (ECOG) performance status \< 2 ( > 60%). Evaluation of ECOG is to be performed within 7 days prior to the start of study treatment.
  4. The effects of pembrolizumab on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate for the duration of study participation and 120 days after last administration of study treatment.

    • Female participants are eligible if not pregnant, not breastfeeding, and one of the following:

      • Not a woman of childbearing potential (WOCBP) OR
      • WOCBP who agrees to follow contraceptive guidance during treatment period and at least 120 days following last dose of study treatment.
    • Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
    • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 120 days after last administration of study treatment. Men should also refrain from donating sperm during this period.
  5. Participants must have either

    • progressive disease after prior anti-BCMA CAR-T therapy and have not started another systemic anti-cancer therapy following progression after anti-BCMA CAR-T therapy. Patients who received localized radiotherapy alone for symptomatic relief of progressive disease following anti-BCMA CAR-T will be allowed.
    • OR
    • b. stable disease as best hematologic response after at least 30 days post anti-BCMA CAR-T infusion.

    Progression after anti-BCMA CAR-T is defined by International Myeloma Working Group (IMWG) criteria:

    1. Increase of > 25% from lowest response value in any one or more of the following:

      • Serum M-component and/or (the absolute increase must be > 0.5 g/dL).
      • Urine M-component and/or (the absolute increase must be > 200 mg/24 h).
      • Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be > 10 mg/dL.
      • Bone marrow plasma cell percentage: the absolute percentage must be > 10%.
    2. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas and/or
    3. Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.
  6. Time from date of anti-BCMA CAR-T infusion to date of first administration of pembrolizumab (study drug) must be ≥ 30 days. In order to be eligible for this study, participants must not be candidates for treatment regimens known to provide clinical benefit in MM as assessed by the treating physician and must have previously received or are intolerant to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
  7. Diagnosis of symptomatic multiple myeloma defined as: clonal bone marrow plasma cells > 10% or -proven bony or extramedullary plasmacytoma and any one or more of the following calcium elevation, renal insufficiency, anemia, and bone abnormalities (CRAB) features and myeloma-defining events.

    1. Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the or > 2.75 mmol/L (> 11 mg/dL).
    2. Renal insufficiency: \< 40 mL per minute or serum creatinine > 177 micromol/L (> 2 mg/dL).
    3. Anemia: value of >20g/L below the lowest limit of normal, or a hemoglobin value \<100 g/L.
    4. Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)/CT. If bone marrow has \< 10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement.
    5. Any one or more of the following biomarkers of :

      • 60% or greater clonal plasma cells on bone marrow examination.
      • Serum involved / uninvolved free light chain ratio of 100 or greater, provided the absolute level of the involved light chain is at least 100 mg/L.
      • More than one focal lesion on magnetic resonance imaging (MRI) that is at least 5mm or greater in size.
  8. Active and , defined by serum paraprotein (M-protein) >= 0.5 g/dL, 24-hour urine Bence Jones protein of >= 200 mg, or abnormal serum free light chain ratio with involved light chain of >= 10 mg/dL (100 mg/L).
  9. Have adequate organ function as defined below. Specimens must be collected within 10 days prior to the start of study treatment:

    1. (ANC) >= 500/microliter (uL) (within 10 days prior to the start of study treatment).
    2. >= 25 000/uL (within 10 days prior to the start of study treatment).
    3. Hemoglobin >= 8.0 g/dL (within 10 days prior to the start of study treatment).

      • Growth factor and/or transfusion support is permissible to stabilize participant prior to study treatment if needed.
      • No lower limit if cytopenia is related to bone marrow involvement.
    4. Creatinine =\< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (CrCl) >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (within 10 days prior to the start of study treatment).

      • (GFR) can also be used in place of creatinine or CrCl.
      • Creatinine clearance (CrCl) should be calculated per institutional standard.
    5. Total =\< 1.5 x ULN OR direct bilirubin =\< ULN for participants with total bilirubin levels > 1.5 x ULN (within 10 days prior to the start of study treatment).
    6. (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT)) =\< 2.5 x ULN (=\< 5 x ULN for participants with liver ) (within 10 days prior to the start of study treatment).

Exclusion criteria

Exclusion Criteria:

  1. A who has a positive urine pregnancy test within 72 hours prior to study treatment initiation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    * Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.

  2. Has received prior therapy with an anti-programmed cell death protein 1 (anti ), anti-programmed death-ligand 1 (anti PD-L1), or anti programmed cell death 1 ligand 2 (anti PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX 40, Cluster of Differentiation 137 (CD137)).
  3. Has received prior systemic anti-cancer therapy including agents within 4 weeks prior to study treatment initiation.

    1. Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =\< grade 1 or baseline. Participants with =\< grade 2 neuropathy may be eligible.
    2. Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
  4. Has received anti-BCMA CAR-T infusion \< 30 days prior to study treatment initiation.
  5. Has received subsequent systemic anti-cancer therapy following anti-BCMA CAR-T therapy. Participants who received localized radiotherapy alone for symptom control following anti-BCMA CAR-T therapy will be allowed to participate.
  6. Has received a within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are generally Messenger RNA (mRNA)-based or viral vector vaccines (replication-incompetent) and are allowed.
  7. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.

    * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent

  8. Has a diagnosis of primary immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug.
  9. Has an active history of a second requiring treatment, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Participants with the following low-risk or non-invasive malignancies will be allowed:

    1. Basal cell carcinoma of the skin.
    2. Squamous cell carcinoma of the skin.
    3. Carcinoma in-situ of the cervix.
    4. Carcinoma in-situ of the breast.
    5. Superficial bladder cancer.
    6. Incidental histologic finding of prostate cancer (T1a or T1b using the Classification of Malignant Tumors (TNM) [tumor, nodes, ] clinical staging system) or prostate cancer that is curative or considered very-low or low risk in which observation is reasonable.
    7. Other in-situ cancers. * Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ cancers.
  10. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention
  11. Has severe (>= grade 3) to pembrolizumab and/or any of its .
  12. Has active disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  13. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  14. Has an active infection requiring systemic therapy. Prophylactic antibiotics/antivirals are allowed.
  15. Has a known history of (HIV) infection.
  16. Has known active virus infection (defined as Hepatitis B (HBV) deoxyribonucleic acid (DNA) detected or Hepatitis B surface antigen (HbsAg) positive) or known active virus infection (defined as Hepatitis C (HCV) ribonucleic acid (RNA) qualitative detected). Subjects who have been vaccinated against hepatitis B (positive for hepatitis B surface antibody (HBsAB)) who are negative for other markers of prior hepatitis B infection (e.g., Hepatitis B core antibody (HBcAb) negative) are eligible. Subjects with past exposure or known history of hepatitis B infection (e.g., HBcAb positive) are eligible for the study provided that they are negative by assessment for HBV DNA and HbsAg. Subjects with a history of hepatitis C infection (defined as detectable HCV antibody) are eligible as long as they have a negative HCV viral load.
  17. Has a known history of active Bacillus Tuberculosis (TB).
  18. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  19. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  20. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
  21. Has had a history of allogenic bone marrow/tissue/solid organ transplant.
  22. Has unmeasurable disease by serum/urine testing (oligo-secretory or non-secretory multiple myeloma).
  23. Has diagnosis of Waldenstrom's disease, light chain amyloidosis, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) disease.
  24. performance status >= 2.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Treatment (pembrolizumab)

    Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

    Biological: Pembrolizumab

Interventions

  • BiologicalPembrolizumab

    Given IV

    Also known as: Keytruda, Lambrolizumab, MK-3475

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    The International Myeloma Working Group (IMWG) uniform response criteria will be used to assess disease response and progression. The response rate is defined as the proportion of patients achieving a partial response (PR), very good partial response (VGPR), complete response (CR), or a stringent complete response (sCR) after 4 cycles of pembrolizumab therapy. A 95% confidence interval will also be reported.

    Time frame: Up to 4 cycles (1 cycle is equal to 21 days)

Secondary outcomes

  1. Proportion of Participants With Reported Treatment-related Adverse Events

    The safety population will consist of all participants who receive any amount of study treatment. Safety will be assessed by evaluation of AEs using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Specific AEs will be counted once for each participant for calculating rates but will be presented in total in participant listings including frequency of non-hematologic grade 3 or higher adverse events.

    Time frame: Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

  2. Proportion of Participants With Cytokine Release Syndrome (CRS)

    Proportion of participants with reported CRS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported.

    Time frame: Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

  3. Proportion of Participants With Immune-effector Cell-associated Neurotoxicity Syndrome (ICANS)

    The Proportion of participants with reported ICANS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported

    Time frame: Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

  4. Proportion of Participants Discontinuing Treatment Due to Toxicity

    The proportion of participants who reported discontinuing treatment due to a treatment-related toxicity will be reported.

    Time frame: Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

  5. Proportion of Participants by Best Achieved Response Rate

    The proportion of patients achieving progressive disease, stable disease, partial response, very good partial response, complete response, stringent complete response for best-achieved response, using the IMWG criteria for assessing response, at any time during pembrolizumab therapy will be reported.

    Time frame: Approximately 1 year and 8 months

  6. Median Overall Survival (OS) at 12 Months

    For OS, participants who remain alive at the end of study follow-up will be censored at the time when the participants is known to be alive. Results will be summarized using the Kaplan-Meier method. The 12-months percentage of participants alive, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

    Time frame: Up to 2 years

  7. Median Progression-Free Survival (PFS) at 12 Months

    For PFS, participants without progression or death will be censored at the time of the last evaluable disease assessment, while participants without a disease assessment will be censored at the date of first study treatment received. Results will be summarized using the Kaplan-Meier method. The 12-months event-free probabilities, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

    Time frame: Up to 1 year

  8. Median Progression-Free Survival (PFS) at 24 Months

    For PFS, participants without progression or death will be censored at the time of the last evaluable disease assessment, while participants without a disease assessment will be censored at the date of first study treatment received. Results will be summarized using the Kaplan-Meier method. The 24-months event-free probabilities, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

    Time frame: Up to 2 years

  9. Median Duration of Response (DOR)

    Median duration of response among the responders will be reported along with 95% confidence intervals.

    Time frame: Up to 2 years

  10. Cumulative Incidence Function for Time to Next Treatment (TNT)

    Competing risks analysis will be performed for analyzing TNT, with death as a competing event. For patients who are alive and do not receive the next line of therapy, TNT will be censored at the last study contact. Cumulative incidence function, along with 95% confidence intervals, will be reported for TNT.

    Time frame: Up to 2 years

07

Results

Posted Jan 15, 2025
Limitations and caveats
The study closed earlier than expected due to slow accrual

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Pembrolizumab)
Started3
Completed3
Not completed0

Outcome measures

PrimaryOverall Response Rate (ORR)

The International Myeloma Working Group (IMWG) uniform response criteria will be used to assess disease response and progression. The response rate is defined as the proportion of patients achieving a partial response (PR), very good partial response (VGPR), complete response (CR), or a stringent complete response (sCR) after 4 cycles of pembrolizumab therapy. A 95% confidence interval will also be reported.

Time frame:
Up to 4 cycles (1 cycle is equal to 21 days)

No measurements were reported for this outcome.

SecondaryProportion of Participants With Reported Treatment-related Adverse Events

The safety population will consist of all participants who receive any amount of study treatment. Safety will be assessed by evaluation of AEs using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Specific AEs will be counted once for each participant for calculating rates but will be presented in total in participant listings including frequency of non-hematologic grade 3 or higher adverse events.

Time frame:
Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months
Reported as:
Count of participants · Participants
Proportion of Participants With Reported Treatment-related Adverse Events
ParticipantsTreatment (Pembrolizumab)
Proportion of Participants With Reported Treatment-related Adverse Events0
SecondaryProportion of Participants With Cytokine Release Syndrome (CRS)

Proportion of participants with reported CRS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported.

Time frame:
Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

No measurements were reported for this outcome.

SecondaryProportion of Participants With Immune-effector Cell-associated Neurotoxicity Syndrome (ICANS)

The Proportion of participants with reported ICANS as defined by the American Society for Transplantation and Cellular Therapy (ASTCT) will be reported

Time frame:
Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

No measurements were reported for this outcome.

SecondaryProportion of Participants Discontinuing Treatment Due to Toxicity

The proportion of participants who reported discontinuing treatment due to a treatment-related toxicity will be reported.

Time frame:
Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months
Reported as:
Number · proportion of participants
Proportion of Participants Discontinuing Treatment Due to Toxicity
proportion of participantsTreatment (Pembrolizumab)
Proportion of Participants Discontinuing Treatment Due to Toxicity0
SecondaryProportion of Participants by Best Achieved Response Rate

The proportion of patients achieving progressive disease, stable disease, partial response, very good partial response, complete response, stringent complete response for best-achieved response, using the IMWG criteria for assessing response, at any time during pembrolizumab therapy will be reported.

Time frame:
Approximately 1 year and 8 months

No measurements were reported for this outcome.

SecondaryMedian Overall Survival (OS) at 12 Months

For OS, participants who remain alive at the end of study follow-up will be censored at the time when the participants is known to be alive. Results will be summarized using the Kaplan-Meier method. The 12-months percentage of participants alive, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryMedian Progression-Free Survival (PFS) at 12 Months

For PFS, participants without progression or death will be censored at the time of the last evaluable disease assessment, while participants without a disease assessment will be censored at the date of first study treatment received. Results will be summarized using the Kaplan-Meier method. The 12-months event-free probabilities, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

Time frame:
Up to 1 year

No measurements were reported for this outcome.

SecondaryMedian Progression-Free Survival (PFS) at 24 Months

For PFS, participants without progression or death will be censored at the time of the last evaluable disease assessment, while participants without a disease assessment will be censored at the date of first study treatment received. Results will be summarized using the Kaplan-Meier method. The 24-months event-free probabilities, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryMedian Duration of Response (DOR)

Median duration of response among the responders will be reported along with 95% confidence intervals.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryCumulative Incidence Function for Time to Next Treatment (TNT)

Competing risks analysis will be performed for analyzing TNT, with death as a competing event. For patients who are alive and do not receive the next line of therapy, TNT will be censored at the last study contact. Cumulative incidence function, along with 95% confidence intervals, will be reported for TNT.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Pembrolizumab)0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Most frequent other events
EventTreatment (Pembrolizumab)
DiarrheaGastrointestinal disorders1/3
NauseaGastrointestinal disorders1/3
Oral painGastrointestinal disorders1/3
AnemiaBlood and lymphatic system disorders1/3
Weight LossInvestigations1/3

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treatment (Pembrolizumab)
50-59 years1
60-69 years1
70-79 years1
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Pembrolizumab)
Female0
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Pembrolizumab)
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Pembrolizumab)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Pembrolizumab)
United States3
08

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2023, 19 months.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2022
First posted
Jan 13, 2022
StartActual
May 3, 2022
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Results first posted
Jan 15, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05191472
Lead sponsor
Alfred Chung, MD
Responsible party
Alfred Chung, MD (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Jan 13, 2022
Start date
May 3, 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Results posted
Jan 15, 2025
Last update
Jan 15, 2025

Study contacts

Alfred Chung, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion